The case for & against
Bull & Bear analysis
Bullish
Tactile Systems Technology, Inc. (NASDAQ: TCMD) is a medical device company specializing in solutions for patients with lymphedema and chronic airway clearance needs. It operates within the growing healthcare market, focusing on integrating innovative therapies to enhance patient care outcomes and mitigate the impact of chronic diseases. The company employs a market-leading position in areas like lymphedema treatment while aggressively navigating regulatory changes impacting the Medicare reimbursement landscape.
Bull says
- ↑Q1 revenue $75.3M (+23% YoY); lymphedema segment drove $62.2M
- ↑Full-year revenue guidance lifted to $360–368M (+9–12% YoY)
- ↑Gross margin expanded to 76.5% (+250bps), boosting operational leverage
- ↑Lymphatech acquisition enhances diagnostics; Nimble device growing faster than market
- ↑Strong Buy consensus; 33.7% upside to $38.60 average target
- ↑Aging population and improved reimbursement support chronic disease demand
Bear says
- ↓Medicare prior authorization may delay revenue recognition and sales cadence
- ↓Lymphatech integration risks may postpone expected financial returns
- ↓Operating expenses rose 19% YoY to $59.1M, pressuring net margins
- ↓Analysts have cut forecasts; negative revisions signal weakening sentiment
- ↓Profitability factors weak; sensitivity to oil and size raise volatility
- ↓Regulatory and reimbursement complexity could impede product adoption pace
Investment themes with TCMD
Buybacks↓ -0.29%
Companies repurchasing their own shares
C · JCI · WFC
Earnings Call · Q3 2023 · Mgmt. Guidance
Updated 12-03-2024neutral
Transcript signals
Bull points
- I was really pleased with our team's performance in the third quarter with $69.6 million of total revenue. We posted our fourth quarter in a row of double digit lymphedema growth and exceeded our overall revenue and profit expectations for the quarter.
- In addition to our solid total revenue performance, we also achieved another quarter of profitability with year-over-year improvements in both our net income and adjusted EBITDA.
- $4.1 million
Bear points
- our year-over-year sales performance in the third quarter continued to be impacted by the dynamic we discussed on our earnings call in August, with one large DME customer experiencing slowed placements of our AffloVest system.
- Looking ahead, we expect the expiration of the PHE waiver will remain an ongoing headwind to the performance of this large DME customer until they reach its anniversary in May of next year.
- sales of our airway clearance products, which includes our AffloVest system, decreased $4 million, or 35.9% to $7.1 million.
Read full transcript analysis ›